FOSTER CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the closing of its initial public offering of 17,968,750 shares of common stock, which includes the full exercise of the underwriters’ option to purchase 2,343,750 additional shares of common stock, at a public offering price of $16.00 per share. All of the shares were offered by Vaxcyte. The aggregate gross proceeds from the offering were $287.5 million, before deducting underwriting discounts and commissions and offering expenses. The shares began trading on the Nasdaq Global Select Market under the ticker symbol “PCVX” on June 12,
